Skip to main content
. 2021 Sep 16;15:745178. doi: 10.3389/fncel.2021.745178

Figure 3.

Figure 3

Analgesic tolerance to SNC80 is abolished in GFAP-DOR-KO female mice. (A,B) Experimental design in males and females. SNC80-induced analgesia and analgesic tolerance was scored in neuropathic GFAP-DOR-KO and DOR-flox males (A) and females (B). (C) Mechanical sensitivity in males each day before SCN80 administration, ipsilateral side. (D) Mechanical sensitivity at ipsilateral side in males following SCN80 administration shows analgesic tolerance in each genotype and no genotype difference. (E) Sensitivity in males each day before SCN80 administration, contralateral side. (F) Sensitivity in males each day after SCN80 administration, contralateral side. n = 13 DOR-flox males, n = 11 GFAP-DOR-KO males, two-way repeated measures ANOVA and one-way repeated measures ANOVA on each genotype followed by Sidak’s multiple comparison tests. (G) Mechanical sensitivity at ipsilateral side in females each day before SCN80 administration. (H) Mechanical sensitivity following SCN80 administration shows that analgesic tolerance occurred in DOR-flox females but did not develop in GFAP-DOR-KO females. (I) Sensitivity in females each day before SCN80 administration, contralateral side. (J) Sensitivity in females each day after SCN80 administration, contralateral side. n = 10 DOR-flox females, n = 7 GFAP-DOR-KO females, mixed effect analysis for genotype comparison followed by Sidak’s multiple comparison test and mixed effect analysis of each genotype followed by Wilcoxon test. P-values for the difference between genotypes are shown when significant (p < 0.05). Data are expressed as mean ± SEM. See also Supplementary Table 3 for statistics.